PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31115561-8	2019	Typically, LY2228820, the p38 inhibitor (3 nM) would mitigate the pro-inflammatory effects of anti-miRNA-22 in the in vitro model.	ralimetinib	11-20	mitogen activated protein kinase 14	Rattus norvegicus	26-29
18397345-0	2008	p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.	ralimetinib	47-56	mitogen-activated protein kinase 14	Homo sapiens	0-36
18397345-2	2008	This study investigated the therapeutic potential of novel p38 mitogen-activated protein kinase (p38MAPK) inhibitor LY2228820 (LY) in MM.	ralimetinib	116-125	mitogen-activated protein kinase 14	Homo sapiens	59-95
18397345-2	2008	This study investigated the therapeutic potential of novel p38 mitogen-activated protein kinase (p38MAPK) inhibitor LY2228820 (LY) in MM.	ralimetinib	116-125	mitogen-activated protein kinase 14	Homo sapiens	97-104
18397345-2	2008	This study investigated the therapeutic potential of novel p38 mitogen-activated protein kinase (p38MAPK) inhibitor LY2228820 (LY) in MM.	ralimetinib	116-118	mitogen-activated protein kinase 14	Homo sapiens	59-95
18397345-2	2008	This study investigated the therapeutic potential of novel p38 mitogen-activated protein kinase (p38MAPK) inhibitor LY2228820 (LY) in MM.	ralimetinib	116-118	mitogen-activated protein kinase 14	Homo sapiens	97-104
31720084-3	2019	Here, we reported that LY2228820, a selective inhibitor of p38-MAPK signaling pathway, could induce synergistic anti-cancer effects with anti-microtubule (AMT) chemotherapy both in vitro and in vivo.	ralimetinib	23-32	mitogen-activated protein kinase 14	Homo sapiens	59-62
31720084-9	2019	Furthermore, LY2228820 blocked the p-HSP27 mediated protective response against AMT drugs in tumor cells, resulting in mitochondrial instability and the activation of mitochondrial death pathways.	ralimetinib	13-22	heat shock protein family B (small) member 1	Homo sapiens	37-42
31720084-10	2019	This P-gp-independent regime containing LY2228820 and AMT agents could produce synergistic anti-cancer effects without extra systematic toxicity.	ralimetinib	40-49	phosphoglycolate phosphatase	Homo sapiens	5-9
30867799-3	2019	In KRAS-mutated NSCLC cells, the MEK inhibitor, selumetinib, inhibited cell growth in a dose-dependent manner, and its growth-inhibitory effect was enhanced by combined treatment with the p38 inhibitor LY2228820.	ralimetinib	202-211	KRAS proto-oncogene, GTPase	Homo sapiens	3-7
30867799-3	2019	In KRAS-mutated NSCLC cells, the MEK inhibitor, selumetinib, inhibited cell growth in a dose-dependent manner, and its growth-inhibitory effect was enhanced by combined treatment with the p38 inhibitor LY2228820.	ralimetinib	202-211	mitogen-activated protein kinase kinase 7	Homo sapiens	33-36
30867799-3	2019	In KRAS-mutated NSCLC cells, the MEK inhibitor, selumetinib, inhibited cell growth in a dose-dependent manner, and its growth-inhibitory effect was enhanced by combined treatment with the p38 inhibitor LY2228820.	ralimetinib	202-211	mitogen-activated protein kinase 14	Homo sapiens	188-191
27179115-0	2016	Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.	ralimetinib	88-97	mitogen-activated protein kinase 14	Homo sapiens	55-58
28900489-5	2017	A p38 MAPK inhibitor (LY2228820) was employed to inhibit activity of p38 MAPK pathway.	ralimetinib	22-31	mitogen-activated protein kinase 14	Homo sapiens	2-5
28900489-5	2017	A p38 MAPK inhibitor (LY2228820) was employed to inhibit activity of p38 MAPK pathway.	ralimetinib	22-31	mitogen-activated protein kinase 14	Homo sapiens	69-72
28900489-12	2017	LY2228820, which was an important p38 MAPK inhibitor, inhibited Rac3-induced cell invasion and migration of lung adenocarcinoma.	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	34-37
28900489-12	2017	LY2228820, which was an important p38 MAPK inhibitor, inhibited Rac3-induced cell invasion and migration of lung adenocarcinoma.	ralimetinib	0-9	Rac family small GTPase 3	Homo sapiens	64-68
28900489-13	2017	E-cadherin expression was increased and vimentin expression was decreased after silencing of Rac3 or following the treatment of LY2228820.	ralimetinib	128-137	cadherin 1	Homo sapiens	0-10
28900489-13	2017	E-cadherin expression was increased and vimentin expression was decreased after silencing of Rac3 or following the treatment of LY2228820.	ralimetinib	128-137	vimentin	Homo sapiens	40-48
26581242-0	2016	A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.	ralimetinib	76-85	mitogen-activated protein kinase 14	Homo sapiens	43-46
26581242-2	2016	Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK.	ralimetinib	13-22	mitogen-activated protein kinase 14	Homo sapiens	78-81
26913608-4	2016	Inhibition of p38 MAPK signaling in osteolytic PC3 cells by small molecule inhibitors (doramapimod, LY2228820 and SB202190) suppressed DKK-1 expression, whereas activation of p38 MAPK by anisomycin increased DKK-1.	ralimetinib	100-109	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	135-140
26407843-6	2015	In this work, we show that p38 inhibition using SB202190 or LY2228820 potently suppressed DKK-1 expression by MDA-231 and MCF-7 breast cancer cell lines as well melanoma derived MDA-435 cells.	ralimetinib	60-69	mitogen-activated protein kinase 14	Homo sapiens	27-30
26407843-6	2015	In this work, we show that p38 inhibition using SB202190 or LY2228820 potently suppressed DKK-1 expression by MDA-231 and MCF-7 breast cancer cell lines as well melanoma derived MDA-435 cells.	ralimetinib	60-69	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	90-95
23335506-0	2013	LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo.	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	47-83
24356814-0	2014	Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.	ralimetinib	20-29	mitogen-activated protein kinase 14	Homo sapiens	78-81
24356814-4	2014	LY2228820 dimesylate (hereafter LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the alpha- and beta-isoforms of p38 MAPK in vitro (IC(50) = 5.3 and 3.2 nmol/L, respectively).	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	171-174
24356814-4	2014	LY2228820 dimesylate (hereafter LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the alpha- and beta-isoforms of p38 MAPK in vitro (IC(50) = 5.3 and 3.2 nmol/L, respectively).	ralimetinib	32-41	mitogen-activated protein kinase 14	Homo sapiens	171-174
24356814-7	2014	In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg].	ralimetinib	87-96	MAPK activated protein kinase 2	Homo sapiens	58-61
24356814-7	2014	In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg].	ralimetinib	87-96	MAPK activated protein kinase 2	Homo sapiens	65-68
24356814-10	2014	In summary, LY2228820 is a p38 MAPK inhibitor, which has been optimized for potency, selectivity, drug-like properties (such as oral bioavailability), and efficacy in animal models of human cancer.	ralimetinib	12-21	mitogen-activated protein kinase 14	Homo sapiens	27-30
23335506-1	2013	LY2228820 dimesylate is a highly selective small molecule inhibitor of p38alpha and p38beta mitogen-activated protein kinases (MAPKs) that is currently under clinical investigation for human malignancies.	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	71-79
23335506-1	2013	LY2228820 dimesylate is a highly selective small molecule inhibitor of p38alpha and p38beta mitogen-activated protein kinases (MAPKs) that is currently under clinical investigation for human malignancies.	ralimetinib	0-9	mitogen-activated protein kinase 11	Homo sapiens	84-91
23335506-5	2013	p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.	ralimetinib	95-104	mitogen-activated protein kinase 14	Homo sapiens	0-3
23335506-5	2013	p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.	ralimetinib	95-104	vascular endothelial growth factor A	Homo sapiens	160-165
23335506-5	2013	p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.	ralimetinib	95-104	fibroblast growth factor 2	Homo sapiens	167-171
23335506-5	2013	p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.	ralimetinib	95-104	epidermal growth factor	Homo sapiens	161-164
23335506-5	2013	p38 MAPK was activated in endothelial cells upon growth factor stimulation, with inhibition by LY2228820 dimesylate treatment causing a significant decrease in VEGF-, bFGF-, EGF-, and IL-6-induced endothelial cord formation and an even more dramatic decrease in tumor-driven cord formation.	ralimetinib	95-104	interleukin 6	Homo sapiens	184-188
23335506-7	2013	LY2228820 dimesylate results were substantiated using p38alpha MAPK-specific shRNA and shRNA against the downstream p38 MAPK effectors MAPKAPK-2 and HSP27.	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	54-62
23335506-7	2013	LY2228820 dimesylate results were substantiated using p38alpha MAPK-specific shRNA and shRNA against the downstream p38 MAPK effectors MAPKAPK-2 and HSP27.	ralimetinib	0-9	mitogen-activated protein kinase 14	Homo sapiens	54-57
23335506-7	2013	LY2228820 dimesylate results were substantiated using p38alpha MAPK-specific shRNA and shRNA against the downstream p38 MAPK effectors MAPKAPK-2 and HSP27.	ralimetinib	0-9	MAPK activated protein kinase 2	Homo sapiens	135-144
23335506-7	2013	LY2228820 dimesylate results were substantiated using p38alpha MAPK-specific shRNA and shRNA against the downstream p38 MAPK effectors MAPKAPK-2 and HSP27.	ralimetinib	0-9	heat shock protein family B (small) member 1	Homo sapiens	149-154
23335506-8	2013	Using in vivo models of functional neoangiogenesis, LY2228820 dimesylate treatment reduced hemoglobin content in a plug assay and decreased VEGF-A-stimulated vascularization in a mouse ear model.	ralimetinib	52-61	vascular endothelial growth factor A	Mus musculus	140-146